TRUST

Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)

Alexander Reuss, Andreas Du Bois, Philipp Harter, Christina Fotopoulou, Jalid Sehouli, Giovanni Aletti, Frederic Guyon, Stefano Greggi, Berit Jul Mosgaard, Alexander Reinthaller, Felix Hilpert, Carmen Schade-Brittinger, Dennis S. Chi, Sven Mahner

Research output: Contribution to journalArticle

Abstract

Background: Primary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC-GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection. Primary Objective: To clarify the optimal timing of surgical therapy in advanced ovarian cancer. Study Hypothesis: Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. Trial Design: TRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery in patients with FIGO stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma. To guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (eg, ≥50% complete resection rate in upfront surgery for FIGO IIIB-IVB patients, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST quality committee delegates. Patients in the primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas patients in the interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy after histologic confirmation of the disease, followed by interval cytoreductive surgery and subsequently, 3 cycles of platinum-based chemotherapy. The intention of surgery for both groups is complete tumor resection according to guideline recommendations. Major Inclusion/Exclusion Criteria: Major inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB-IVB (IV only if resectable metastasis). Major exclusion criteria are non-epithelial ovarian malignancies and borderline tumors; prior chemotherapy for ovarian cancer; or abdominal/pelvic radiotherapy. Primary Endpoint: Overall survival. Sample Size: 772 patients. Estimated Dates for Completing Accrual and Presenting Results: Accrual completion approximately mid-2019, results are expected after 5 years' follow-up in 2024. Trial Registration: NCT02828618.

Original languageEnglish
JournalInternational Journal of Gynecological Cancer
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Ovarian Neoplasms
Drug Therapy
Therapeutics
Platinum
Carcinoma
Survival
Fallopian Tube Neoplasms
Neoplasms
Sample Size
Radiotherapy
Guidelines
Neoplasm Metastasis

Keywords

  • interval debulking surgery
  • neoadjuvant chemotherapy
  • ovarian cancer
  • primary debulking surgery

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

TRUST : Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). / Reuss, Alexander; Du Bois, Andreas; Harter, Philipp; Fotopoulou, Christina; Sehouli, Jalid; Aletti, Giovanni; Guyon, Frederic; Greggi, Stefano; Mosgaard, Berit Jul; Reinthaller, Alexander; Hilpert, Felix; Schade-Brittinger, Carmen; Chi, Dennis S.; Mahner, Sven.

In: International Journal of Gynecological Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Reuss, A, Du Bois, A, Harter, P, Fotopoulou, C, Sehouli, J, Aletti, G, Guyon, F, Greggi, S, Mosgaard, BJ, Reinthaller, A, Hilpert, F, Schade-Brittinger, C, Chi, DS & Mahner, S 2019, 'TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)', International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2019-000682
Reuss, Alexander ; Du Bois, Andreas ; Harter, Philipp ; Fotopoulou, Christina ; Sehouli, Jalid ; Aletti, Giovanni ; Guyon, Frederic ; Greggi, Stefano ; Mosgaard, Berit Jul ; Reinthaller, Alexander ; Hilpert, Felix ; Schade-Brittinger, Carmen ; Chi, Dennis S. ; Mahner, Sven. / TRUST : Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). In: International Journal of Gynecological Cancer. 2019.
@article{a574ed1ebeb94b338053872b29d1270d,
title = "TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)",
abstract = "Background: Primary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC-GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection. Primary Objective: To clarify the optimal timing of surgical therapy in advanced ovarian cancer. Study Hypothesis: Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. Trial Design: TRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery in patients with FIGO stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma. To guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (eg, ≥50{\%} complete resection rate in upfront surgery for FIGO IIIB-IVB patients, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST quality committee delegates. Patients in the primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas patients in the interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy after histologic confirmation of the disease, followed by interval cytoreductive surgery and subsequently, 3 cycles of platinum-based chemotherapy. The intention of surgery for both groups is complete tumor resection according to guideline recommendations. Major Inclusion/Exclusion Criteria: Major inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB-IVB (IV only if resectable metastasis). Major exclusion criteria are non-epithelial ovarian malignancies and borderline tumors; prior chemotherapy for ovarian cancer; or abdominal/pelvic radiotherapy. Primary Endpoint: Overall survival. Sample Size: 772 patients. Estimated Dates for Completing Accrual and Presenting Results: Accrual completion approximately mid-2019, results are expected after 5 years' follow-up in 2024. Trial Registration: NCT02828618.",
keywords = "interval debulking surgery, neoadjuvant chemotherapy, ovarian cancer, primary debulking surgery",
author = "Alexander Reuss and {Du Bois}, Andreas and Philipp Harter and Christina Fotopoulou and Jalid Sehouli and Giovanni Aletti and Frederic Guyon and Stefano Greggi and Mosgaard, {Berit Jul} and Alexander Reinthaller and Felix Hilpert and Carmen Schade-Brittinger and Chi, {Dennis S.} and Sven Mahner",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/ijgc-2019-000682",
language = "English",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - TRUST

T2 - Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)

AU - Reuss, Alexander

AU - Du Bois, Andreas

AU - Harter, Philipp

AU - Fotopoulou, Christina

AU - Sehouli, Jalid

AU - Aletti, Giovanni

AU - Guyon, Frederic

AU - Greggi, Stefano

AU - Mosgaard, Berit Jul

AU - Reinthaller, Alexander

AU - Hilpert, Felix

AU - Schade-Brittinger, Carmen

AU - Chi, Dennis S.

AU - Mahner, Sven

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Primary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC-GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection. Primary Objective: To clarify the optimal timing of surgical therapy in advanced ovarian cancer. Study Hypothesis: Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. Trial Design: TRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery in patients with FIGO stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma. To guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (eg, ≥50% complete resection rate in upfront surgery for FIGO IIIB-IVB patients, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST quality committee delegates. Patients in the primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas patients in the interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy after histologic confirmation of the disease, followed by interval cytoreductive surgery and subsequently, 3 cycles of platinum-based chemotherapy. The intention of surgery for both groups is complete tumor resection according to guideline recommendations. Major Inclusion/Exclusion Criteria: Major inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB-IVB (IV only if resectable metastasis). Major exclusion criteria are non-epithelial ovarian malignancies and borderline tumors; prior chemotherapy for ovarian cancer; or abdominal/pelvic radiotherapy. Primary Endpoint: Overall survival. Sample Size: 772 patients. Estimated Dates for Completing Accrual and Presenting Results: Accrual completion approximately mid-2019, results are expected after 5 years' follow-up in 2024. Trial Registration: NCT02828618.

AB - Background: Primary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC-GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection. Primary Objective: To clarify the optimal timing of surgical therapy in advanced ovarian cancer. Study Hypothesis: Primary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer. Trial Design: TRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery in patients with FIGO stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma. To guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (eg, ≥50% complete resection rate in upfront surgery for FIGO IIIB-IVB patients, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST quality committee delegates. Patients in the primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas patients in the interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy after histologic confirmation of the disease, followed by interval cytoreductive surgery and subsequently, 3 cycles of platinum-based chemotherapy. The intention of surgery for both groups is complete tumor resection according to guideline recommendations. Major Inclusion/Exclusion Criteria: Major inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB-IVB (IV only if resectable metastasis). Major exclusion criteria are non-epithelial ovarian malignancies and borderline tumors; prior chemotherapy for ovarian cancer; or abdominal/pelvic radiotherapy. Primary Endpoint: Overall survival. Sample Size: 772 patients. Estimated Dates for Completing Accrual and Presenting Results: Accrual completion approximately mid-2019, results are expected after 5 years' follow-up in 2024. Trial Registration: NCT02828618.

KW - interval debulking surgery

KW - neoadjuvant chemotherapy

KW - ovarian cancer

KW - primary debulking surgery

UR - http://www.scopus.com/inward/record.url?scp=85071275624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071275624&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2019-000682

DO - 10.1136/ijgc-2019-000682

M3 - Article

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

ER -